Photocure

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. We tweet about #bladdercancer #cancer.

[Photocure @PhotocureASA]

#Bladdercancerawarenessmonth! For the 13th year, Photocure is once again a proud sponsor of the @BladderCancerUS 's Walks to End #Bladdercancer.
This month, our team participated - or will participate - in 13 different local walks throughout the U.S.
Congratulations to BCAN!

[Photocure @PhotocureASA]

In Sweden, Photocure supports a Patient Association information event from Blåscancer Förbundet during #bladdercancerawarenessmonth.
The meeting is on 27 May in Stockholm, 6.00 pm – 7.45 pm.
#bladdercanceraware #medicaleducation #urooncology

[Photocure @PhotocureASA]

Photocure supports the digital #bladdercancer awareness campaign of the Urologische Stiftung Gesundheit: info for patients on bladder cancer symptoms, risk factors and myths, airing throughout 2026.
#bladdercanceraware #bladdercancerawarenessmonth #medicaleducation #urooncology

[Photocure @PhotocureASA]

Photocure today reported Hexvix®/Cysview® revenues of NOK 139.0 million in Q1 2026 (Q1 2025: NOK 125.3 million), and an adjusted EBITDA of NOK 15.3 million (Q1 2025: NOK 9.7 million).
Read more: https://t.co/EIqObx3l6M

[Photocure @PhotocureASA]

Introducing Photocure's 2025 Annual Report and Sustainability Statement. Read more about our commitment to bladder cancer diagnostics, where precision matters. https://t.co/QvSN2WltBD

#annualreport #sustainability #ESG #urooncology #bladdercancer

[Photocure @PhotocureASA]

Photocure is participating in the EAU Congress in London, UK!
Come meet our team at Booth F21.
#EAU26 #BladderCancer #LeadingChange

[Photocure @PhotocureASA]

Photocure today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the Q4 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million). Read more: https://t.co/VGMFbxV7Y3

[Photocure @PhotocureASA]

New UROwebinar: "Bladder preservation – A changing paradigm in treatment"
Organised by the European School of Urology with the support of Photocure: 10 Feb 2026, 18:30-19:30 CET. HCPs register here: https://t.co/CAj7fJ5KyQ
Speakers: P. Gontero, L. S. Mertens, M. Rouprêt

[Photocure @PhotocureASA]

Thank you for your continued support. We certainly had our share of exciting developments in 2025 at Photocure and are looking forward to a fantastic 2026! We wish you all a happy, healthy and successful New Year!
https://t.co/DsCS2hRIk6

[Photocure @PhotocureASA]

Attending the Society of Urologic Oncology 2025 Annual Meeting (SUO) December 2-5, 2025, in Phoenix, Arizona? Meet our teams at the joint Photocure - KARL STORZ booth. Location: Sheraton Phoenix Downtown.

#SUO2025 #bladdercancer #urooncology

[Photocure @PhotocureASA]

Photocure is attending the International Conference on Endourology (ICE25) in Rome, 27–29 November 2025.
We look forward to meeting you at booth N° 11.

#ICE25 #Urology #BladderCancer

[Photocure @PhotocureASA]

Learn more about health economics, key modelling tools, and how insights can impact bladder cancer care. Our experts discuss their latest research.

Watch the video now.
https://t.co/E92paeMQX8

#BladderCancer #healtheconomics #urology

[Photocure @PhotocureASA]

Photocure is attending the 119ᵉ Congrès Français d’Urologie (CFU) in Paris, 19–22 November 2025!
Visit us at Booth B05 at the Palais des Congrès. We look forward to meeting you there.
#CFU2025 #Urology #BladderCancer

[Photocure @PhotocureASA]

“Women and younger people are more likely to be misdiagnosed. Nearly 70% of women were told they had something else, usually a urinary tract infection." (Lydia E Makaroff, PhD, World Bladder Cancer Patient Coalition). Read more https://t.co/dBEO5RyhWM
#bladdercancer #EURoundtable

[Photocure @PhotocureASA]

Photocure today reported Hexvix®/Cysview® revenues of NOK 134.1 million in Q2 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (NOK 5.0 million). Read more: https://t.co/R0I6ywEHPP

[Photocure @PhotocureASA]

Photocure is attending the 98th National Congress of the Italian Society of Urology (SIU) in Sorrento, 6–9 November 2025! Visit us at Booth No. 7 at the Hilton Sorrento Palace. We look forward to meeting you there.
#SIU2025 #Urology #BladderCancer

[Photocure @PhotocureASA]

Photocure supports the next EAU/ESU UROwebinar “TURBT-related challenges in bladder cancer: Nightmare Cases – Part 2”
For Healthcare professionals on 4 Nov 2025, 18:30 CET– register here: https://t.co/IcSuBw7yca
#BladderCancer #Urology #NMIBC #UROwebinar #MedicalEducation

[Photocure @PhotocureASA]

Photocure participated in the EU Roundtable on Bladder Cancer in April. Expert recommendations are now published in the Government Gazette. Read more: https://t.co/eg6SDu583B

#bladdercancer #EUroundtable #precisiondiagnostics

[Photocure @PhotocureASA]

Photocure participated in the EU Roundtable on Bladder Cancer in April. Expert recommendations are now published in the Government Gazette.
Read more: https://t.co/YzkeeuJAth

#bladdercancer #EURoundtable

[Photocure @PhotocureASA]

Urinary tract infections share symptoms with #bladdercancer which can cause delays in diagnosing bladder cancer, especially in women. Earlier diagnosis of bladder cancer is important and may improve outcomes for women.
This #UrologyWeek, find out more: https://t.co/tpe4BBbkKF